IR
HZNP

Invictus RG’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Invictus RG’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,750
Closed -$68K – 786
2017
Q2 		$68K Buy
+5,750
New +$71.5K 0.05% 431
2017
Q1 		– Sell
-11,973
Closed -$194K – 902
2016
Q4 		$194K Buy
11,973
+4,919
+70% +$89.2K 0.13% 313
2016
Q3 		$128K Buy
+7,054
New +$138K 0.1% 366

Other funds holding HZNP

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Invictus RG's HZNP Position: Q3 2017 in Review

Invictus RG sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2017, closing a stake of 5,750 shares — an estimated $68K sold.

Invictus RG first reported a position in HZNP in Q3 2016 and held it in 3 quarters. The position peaked at $194K in Q4 2016. 181 funds tracked by Wall St. Rank hold HZNP as of Q3 2017.

  • Invictus RG reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Invictus RG sold 5,750 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2017, an estimated $68K.
  • Invictus RG first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2016 and held it in 3 quarters.
  • Invictus RG's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $194K in Q4 2016.
  • 181 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2017.

Based on Invictus RG's 13F filing for Q3 2017, filed 13 Nov 2017.